182 related articles for article (PubMed ID: 21109925)
1. Tumor localization of an anti-TGF-β antibody and its effects on gliomas.
Hülper P; Schulz-Schaeffer W; Dullin C; Hoffmann P; Harper J; Kurtzberg L; Lonning S; Kugler W; Lakomek M; Erdlenbruch B
Int J Oncol; 2011 Jan; 38(1):51-9. PubMed ID: 21109925
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
Tran TT; Uhl M; Ma JY; Janssen L; Sriram V; Aulwurm S; Kerr I; Lam A; Webb HK; Kapoun AM; Kizer DE; McEnroe G; Hart B; Axon J; Murphy A; Chakravarty S; Dugar S; Protter AA; Higgins LS; Wick W; Weller M; Wong DH
Neuro Oncol; 2007 Jul; 9(3):259-70. PubMed ID: 17522330
[TBL] [Abstract][Full Text] [Related]
3. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
4. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg.
Biollaz G; Bernasconi L; Cretton C; Püntener U; Frei K; Fontana A; Suter T
Eur J Immunol; 2009 May; 39(5):1323-33. PubMed ID: 19337997
[TBL] [Abstract][Full Text] [Related]
5. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.
Nakamizo A; Marini F; Amano T; Khan A; Studeny M; Gumin J; Chen J; Hentschel S; Vecil G; Dembinski J; Andreeff M; Lang FF
Cancer Res; 2005 Apr; 65(8):3307-18. PubMed ID: 15833864
[TBL] [Abstract][Full Text] [Related]
6. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice.
Phillips PC; Levow C; Catterall M; Colvin OM; Pastan I; Brem H
Cancer Res; 1994 Feb; 54(4):1008-15. PubMed ID: 8313355
[TBL] [Abstract][Full Text] [Related]
8. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
[TBL] [Abstract][Full Text] [Related]
9. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development.
Hong YK; Chung DS; Joe YA; Yang YJ; Kim KM; Park YS; Yung WK; Kang JK
Clin Cancer Res; 2000 Aug; 6(8):3354-60. PubMed ID: 10955823
[TBL] [Abstract][Full Text] [Related]
10. Development of a xenograft glioma model in mouse brain.
Kaye AH; Morstyn G; Gardner I; Pyke K
Cancer Res; 1986 Mar; 46(3):1367-73. PubMed ID: 3943101
[TBL] [Abstract][Full Text] [Related]
11. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
[TBL] [Abstract][Full Text] [Related]
12. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
[TBL] [Abstract][Full Text] [Related]
13. Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth.
Benny O; Menon LG; Ariel G; Goren E; Kim SK; Stewman C; Black PM; Carroll RS; Machluf M
Clin Cancer Res; 2009 Feb; 15(4):1222-31. PubMed ID: 19190128
[TBL] [Abstract][Full Text] [Related]
14. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.
Wesolowska A; Kwiatkowska A; Slomnicki L; Dembinski M; Master A; Sliwa M; Franciszkiewicz K; Chouaib S; Kaminska B
Oncogene; 2008 Feb; 27(7):918-30. PubMed ID: 17684491
[TBL] [Abstract][Full Text] [Related]
15. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.
Ashley DM; Kong FM; Bigner DD; Hale LP
Cancer Res; 1998 Jan; 58(2):302-9. PubMed ID: 9443409
[TBL] [Abstract][Full Text] [Related]
16. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo.
Edwards JR; Nyman JS; Lwin ST; Moore MM; Esparza J; O'Quinn EC; Hart AJ; Biswas S; Patil CA; Lonning S; Mahadevan-Jansen A; Mundy GR
J Bone Miner Res; 2010 Nov; 25(11):2419-26. PubMed ID: 20499365
[TBL] [Abstract][Full Text] [Related]
18. Production and characterization of two human glioma xenograft-localizing monoclonal antibodies.
Wikstrand CJ; McLendon RE; Bullard DE; Fredman P; Svennerholm L; Bigner DD
Cancer Res; 1986 Nov; 46(11):5933-40. PubMed ID: 3756930
[TBL] [Abstract][Full Text] [Related]
19. Glioma gene therapy with soluble transforming growth factor-beta receptors II and III.
Naumann U; Maass P; Gleske AK; Aulwurm S; Weller M; Eisele G
Int J Oncol; 2008 Oct; 33(4):759-65. PubMed ID: 18813789
[TBL] [Abstract][Full Text] [Related]
20. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
